LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)-Reference-Cited by-同舟云学术

LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Published:2023-10 Issue: Volume:34 Page:S1340
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Powles T.B.,Perez Valderrama B.,Gupta S.,Bedke J.,Kikuchi E.,Hoffman-Censits J.,Iyer G.,Vulsteke C.,Park S.H.,Shin S.J.,Castellano Gauna D.E.,Fornarini G.,Li J-R.,Gumus M.,Mar N.,Narayanan S.,Yu X.,Gorla S.,Homet Moreno van der Heijden B.M.S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor;Clinical Genitourinary Cancer;2024-12

2. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer;Urologic Oncology: Seminars and Original Investigations;2024-11

3. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States;Frontiers in Immunology;2024-09-13

4. READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma;ESMO Real World Data and Digital Oncology;2024-09

5. Neue Systemtherapie beim fortgeschrittenen Harnblasenkarzinom;Die Urologie;2024-08-29